降糖药物体外评价模型与筛选技术研究进展
Advances in in vitro assessment models and screening methods for blood glucose-lowering medications
董琳捷 1龙江兰 2张建 3张瑜 2鄢丹2
作者信息
- 1. 首都医科大学附属北京友谊医院北京市临床药学研究所,北京 100050;沈阳药科大学中药学院,辽宁本溪 110016
- 2. 首都医科大学附属北京友谊医院北京市临床药学研究所,北京 100050
- 3. 首都医科大学附属北京友谊医院北京市临床药学研究所,北京 100050;成都中医药大学药学院,四川成都 611137
- 折叠
摘要
糖尿病作为典型的代谢性疾病,已被列为全球公共卫生领域的重大慢病范畴,降血糖药物研发长期以来备受国际新药创制领域关注的热点.降血糖药物体外评价模型与筛选技术是其研发过程中的关键环节,可显著减少后期临床试验的成本和风险,提高药物研发的成功效率.为此,该文对国内外经典和最新前沿的降血糖药物体外评价模型及其原理、方法与关键技术进行梳理,客观述评其优劣、特点、适应范围、实验设计、数据分析等,以期提升降血糖药物体外评价模型与筛选技术的规范性与共识性,服务于降血糖药物相关研发工作.
Abstract
Diabetes,a common metabolic condition,is recognized by the worldwide public health community as a serious chronic illness.International new drug discovery has long been dominated by the study and creation of blood glucose-lowering medications.Important phases in the development process of these medications include the in vitro assessment model and screening methods,which can dramatically lower the costs and risks of subsequent clinical trials and increase the effectiveness and efficiency of drug development.This article reviews the classic and latest cutting-edge in vitro assessment models,principles,methods,and key technologies for blood glucose-lowering medications both domestically and internationally.By objectively evaluating their advantages,disadvantages,characteristics,applicability,experimental design,and data analysis,this article aims to improve the standardization and consensus of in vitro assessment models and screening methods and serve the research and development of blood glucose-lowering medications.
关键词
糖尿病/体外评价模型/筛选技术/创新药物Key words
diabetes/in vitro assessment model/screening methods/innovative drugs引用本文复制引用
基金项目
国家自然科学基金重点项目(82130112)
国家中医药管理局高水平中医药重点学科建设项目(zyyzdxk-2023003)
青年北京学者项目(2022-051)
出版年
2024
NETL
NSTL
万方数据